Clinical Trial

Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial

Study acronym: DEFEND
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated January 24, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
The DEFEND trial will be the world's first clinical trial to study the effectiveness of Paxlovid or Veklury in the prevention of cardiovascular post-acute sequelae of SARS-CoV-2 among hospitalized adults. Additionally, this pilot study will inform the design and conduct of a future full-scale multi-centre trial by testing the feasibility and accuracy of this study design.
Trial Details
NCT Number NCT06792214
Lead Sponsor Mount Sinai Hospital, Canada
Collaborators: Unity Health Toronto, Kingston Health Sciences Centre, Niagara Health System
Conditions SARS CoV-2 Post-Acute Sequelae
Enrollment 118 participants
Start Date 2025-01-03
Primary Completion 2026-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-24